Does BillionToOne Have Another Major Growth Engine Beyond Prenatal Testing? The quiet ascent of BillionToOne in the diagnostics sector has been notable for its precision molecular diagnostics technology.
This technology quantifies biology to create more accurate genetic tests, particularly evident in the company's UNITY test for prenatal care. BillionToOne's market capitalization has surged to $6.
32 billion following a 16. 33% one month return and a 67. 79% gain over the past year.